Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.

Mol Ther. 2019 Jul 30. pii: S1525-0016(19)30328-4. doi: 10.1016/j.ymthe.2019.07.015. [Epub ahead of print]

PMID:
31420241
2.

A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.

Randall LM, Wenham RM, Low PS, Dowdy SC, Tanyi JL.

Gynecol Oncol. 2019 Oct;155(1):63-68. doi: 10.1016/j.ygyno.2019.07.010. Epub 2019 Jul 27.

PMID:
31362825
3.

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G.

Cancer Cell. 2019 Jun 10;35(6):885-900.e10. doi: 10.1016/j.ccell.2019.05.004.

PMID:
31185212
4.

Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment.

Hu Z, Zhou J, Jiang J, Yuan J, Zhang Y, Wei X, Loo N, Wang Y, Pan Y, Zhang T, Zhong X, Long M, Montone KT, Tanyi JL, Fan Y, Wang TL, Shih IM, Hu X, Zhang L.

Nat Commun. 2019 Feb 13;10(1):733. doi: 10.1038/s41467-019-08554-x.

5.

Personalized vaccination against ovarian cancer: what are the possibilities?

Tanyi JL, George E.

Expert Rev Vaccines. 2018 Nov;17(11):955-958. doi: 10.1080/14760584.2018.1541743. Epub 2018 Nov 7. No abstract available.

6.

Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.

Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L.

Cancer Cell. 2018 Oct 8;34(4):549-560.e9. doi: 10.1016/j.ccell.2018.08.019.

7.

RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells.

Lin X, Shen J, Dan Peng, He X, Xu C, Chen X, Tanyi JL, Montone K, Fan Y, Huang Q, Zhang L, Zhong X.

Signal Transduct Target Ther. 2018 Aug 31;3:23. doi: 10.1038/s41392-018-0026-5. eCollection 2018.

8.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr, Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
9.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

10.

Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.

Uribe-Herranz M, Bittinger K, Rafail S, Guedan S, Pierini S, Tanes C, Ganetsky A, Morgan MA, Gill S, Tanyi JL, Bushman FD, June CH, Facciabene A.

JCI Insight. 2018 Feb 22;3(4). pii: 94952. doi: 10.1172/jci.insight.94952. eCollection 2018 Feb 22.

11.

Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.

Nabavizadeh N, Waller JG, Fain R 3rd, Chen Y, Degnin CR, Elliott DA, Mullins BT, Patel IA, Dyer BA, Fakhoury K, Naugler WE, Farsad K, Tanyi JA, Fuss M, Thomas CR Jr, Hung AY.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):577-585. doi: 10.1016/j.ijrobp.2017.11.030. Epub 2017 Nov 27.

PMID:
29413273
12.

Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.

Katsnelson M, Hwang WT, Tahirovic E, Rubin SC, Tanyi JL.

J Obstet Gynaecol. 2018 Apr;38(3):395-401. doi: 10.1080/01443615.2017.1336613. Epub 2018 Jan 31.

PMID:
29385863
13.

Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.

O'Hara MH, Stashwick C, Plesa G, Tanyi JL.

Immunotherapy. 2017 Aug;9(9):767-780. doi: 10.2217/imt-2017-0026. Epub 2017 Aug 3. Review.

PMID:
28771103
14.

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.

Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.

Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.

15.

Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.

Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.

J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.

PMID:
28234665
16.

Prevalence of maternal HIV infection and knowledge on mother-to-child transmission of HIV and its prevention among antenatal care attendees in a rural area in northwest Cameroon.

Sama CB, Feteh VF, Tindong M, Tanyi JT, Bihle NM, Angwafo FF 3rd.

PLoS One. 2017 Feb 15;12(2):e0172102. doi: 10.1371/journal.pone.0172102. eCollection 2017.

17.

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F.

JCI Insight. 2017 Jan 12;2(1):e89760. doi: 10.1172/jci.insight.89760.

18.

Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer.

Zhong X, Zheng L, Shen J, Zhang D, Xiong M, Zhang Y, He X, Tanyi JL, Yang F, Montone KT, Chen X, Xu C, Xiang AP, Huang Q, Xu X, Zhang L.

Mol Cell Biol. 2016 Oct 13;36(21):2742-2754. doi: 10.1128/MCB.00079-16. Print 2016 Nov 1.

19.

Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.

Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr.

Gynecol Oncol. 2016 Oct;143(1):120-127. doi: 10.1016/j.ygyno.2016.07.105. Epub 2016 Jul 25.

PMID:
27470997
20.

Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.

Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL.

Oncotarget. 2016 Jul 26;7(30):48577-48585. doi: 10.18632/oncotarget.9373.

21.

Opportunities in immunotherapy of ovarian cancer.

Coukos G, Tanyi J, Kandalaft LE.

Ann Oncol. 2016 Apr;27 Suppl 1:i11-i15. doi: 10.1093/annonc/mdw084. Review.

22.

Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer.

Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L.

Nat Struct Mol Biol. 2016 Jun;23(6):522-30. doi: 10.1038/nsmb.3211. Epub 2016 Apr 25.

23.

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

O'Hara M, Stashwick C, Haas AR, Tanyi JL.

Immunotherapy. 2016;8(4):449-60. doi: 10.2217/imt.16.4. Review.

24.

Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers.

Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, Fan L, Kandalaft LE, Tanyi JL, Li C, Yuan CX, Zhang D, Yuan H, Hua K, Lu Y, Katsaros D, Huang Q, Montone K, Fan Y, Coukos G, Boyd J, Sood AK, Rebbeck T, Mills GB, Dang CV, Zhang L.

Cancer Cell. 2015 Oct 12;28(4):529-540. doi: 10.1016/j.ccell.2015.09.006.

25.

Overexpression of GPC6 and TMEM132D in Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival.

Karapetsas A, Giannakakis A, Dangaj D, Lanitis E, Kynigopoulos S, Lambropoulou M, Tanyi JL, Galanis A, Kakolyris S, Trypsianis G, Coukos G, Sandaltzopoulos R.

Biomed Res Int. 2015;2015:712438. doi: 10.1155/2015/712438. Epub 2015 Sep 13.

26.

A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma.

Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Morgan MA, Uribe-Herranz M, Tanyi JL, Facciabene A.

J Immunol. 2015 Oct 15;195(8):4020-7. doi: 10.4049/jimmunol.1500281. Epub 2015 Sep 16.

27.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, Hagemann IS, Levine BL, June CH, Zhang L, Wang E, Marincola FM, Bedognetti D, Powell DJ Jr, Tanyi J, Feldman MD, Kandalaft LE, Coukos G.

Clin Cancer Res. 2015 Jun 15;21(12):2840-50. doi: 10.1158/1078-0432.CCR-14-2777. Epub 2015 Feb 23.

28.

The impact of anatomic tumor location on inter-fraction tumor motion during lung stereotactic body radiation therapy (SBRT).

Atkins KM, Chen Y, Elliott DA, Doshi TS, Ognjenovic S, Vachhani AS, Kishore M, Primack SL, Fuss M, Deffebach ME, Kubicky CD, Tanyi JA.

J Radiosurg SBRT. 2015;3(3):203-213.

29.

A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer.

Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, Jean S, Li C, Huang Q, Katsaros D, Montone KT, Tanyi JL, Lu Y, Boyd J, Nathanson KL, Li H, Mills GB, Zhang L.

Cancer Cell. 2014 Sep 8;26(3):344-357. doi: 10.1016/j.ccr.2014.07.009.

30.

MLH1 and MSH2 mutation screening in HNPCC families of Hungary - Two new MMR gene mutations.

Tanyi M, Olasz J, Tanyi JL, Tóth L, Antal-Szalmás P, Ress Z, Bubán T, Palatka K, András C, Urbancsek H, Garami Z, Csuka O, Damjanovich L.

Eur J Surg Oncol. 2014 Nov;40(11):1445-52. doi: 10.1016/j.ejso.2014.07.032. Epub 2014 Jul 24.

PMID:
25107687
31.

Immunotherapy for ovarian cancer: recent advances and perspectives.

Zsiros E, Tanyi J, Balint K, Kandalaft LE.

Curr Opin Oncol. 2014 Sep;26(5):492-500. doi: 10.1097/CCO.0000000000000111. Review.

PMID:
25036883
32.

Surgical diagnosis of stage I fallopian tube cancer in anti-Yo antibody paraneoplastic cerebellar degeneration.

Haggerty AF, Mantia-Smaldone G, Siegelman E, Livolsi V, Tanyi J.

J Obstet Gynaecol. 2015 Jan;35(1):100-1. doi: 10.3109/01443615.2014.930095. Epub 2014 Jun 24. No abstract available.

PMID:
24960213
33.

Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.

Giannakakis A, Karapetsas A, Dangaj D, Lanitis E, Tanyi J, Coukos G, Sandaltzopoulos R.

Int J Biochem Cell Biol. 2014 Aug;53:389-98. doi: 10.1016/j.biocel.2014.05.031. Epub 2014 May 29.

PMID:
24880093
34.

Volumetric-modulated arc radiotherapy for pancreatic malignancies: dosimetric comparison with sliding-window intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy.

Nabavizadeh N, Simeonova AO, Waller JG, Romer JL, Monaco DL, Elliott DA, Tanyi JA, Fuss M, Thomas CR Jr, Holland JM.

Med Dosim. 2014 Autumn;39(3):256-60. doi: 10.1016/j.meddos.2014.04.001. Epub 2014 May 23.

PMID:
24857696
35.

Electromagnetic navigational bronchoscopy-guided fiducial markers for lung stereotactic body radiation therapy: analysis of safety, feasibility, and interfraction stability.

Nabavizadeh N, Zhang J, Elliott DA, Tanyi JA, Thomas CR Jr, Fuss M, Deffebach M.

J Bronchology Interv Pulmonol. 2014 Apr;21(2):123-30. doi: 10.1097/LBR.0000000000000065.

PMID:
24739685
36.

Heavy PETting: reducing radiation exposure from intradepartment positron emission tomography scans.

Bornstein S, Young K, Tanyi J, Holland J.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):545. doi: 10.1016/j.ijrobp.2013.11.015. Epub 2013 Dec 21. No abstract available.

PMID:
24368063
37.

Real-time prostate motion assessment: image-guidance and the temporal dependence of intra-fraction motion.

Cramer AK, Haile AG, Ognjenovic S, Doshi TS, Reilly WM, Rubinstein KE, Nabavizadeh N, Nguyen T, Meng LZ, Fuss M, Tanyi JA, Hung AY.

BMC Med Phys. 2013 Sep 23;13(1):4. doi: 10.1186/1756-6649-13-4.

38.

Predicting time to ovarian carcinoma recurrence using protein markers.

Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG.

J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. Erratum in: J Clin Invest. 2013 Dec 2;123(12):5410.

39.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G.

Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.

40.

Circumferential or sectored beam arrangements for stereotactic body radiation therapy (SBRT) of primary lung tumors: effect on target and normal-structure dose-volume metrics.

Rosenberg MW, Kato CM, Carson KM, Matsunaga NM, Arao RF, Doss EJ, McCracken CL, Meng LZ, Chen Y, Laub WU, Fuss M, Tanyi JA.

Med Dosim. 2013 Winter;38(4):407-12. doi: 10.1016/j.meddos.2013.05.002. Epub 2013 Jun 28.

PMID:
23810414
41.

Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer.

Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW.

J Proteomics. 2013 Aug 26;89:165-78. doi: 10.1016/j.jprot.2013.06.016. Epub 2013 Jun 21.

42.

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R, Coukos G.

J Transl Med. 2013 Jun 18;11:149. doi: 10.1186/1479-5876-11-149.

43.

Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.

Beer LA, Wang H, Tang HY, Cao Z, Chang-Wong T, Tanyi JL, Zhang R, Liu Q, Speicher DW.

PLoS One. 2013;8(3):e60129. doi: 10.1371/journal.pone.0060129. Epub 2013 Mar 27.

44.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Kandalaft LE, Powell DJ Jr, Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA, June CH, Coukos G.

Oncoimmunology. 2013 Jan 1;2(1):e22664.

45.

The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer.

Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, Huang Q, Zhang L.

Mol Cancer Res. 2013 Mar;11(3):240-50. doi: 10.1158/1541-7786.MCR-12-0432. Epub 2013 Jan 21.

46.

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA.

Int J Gynecol Cancer. 2013 Feb;23(2):348-54. doi: 10.1097/IGC.0b013e31827c18f3.

47.

mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human cancer cells.

Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L.

Biochem Biophys Res Commun. 2013 Feb 15;431(3):617-22. doi: 10.1016/j.bbrc.2012.12.083. Epub 2012 Dec 27.

48.

Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.

Tanyi JL, Chu CS.

Immunotherapy. 2012 Oct;4(10):995-1009. doi: 10.2217/imt.12.100. Review.

PMID:
23148752
49.

Dynamic conformal arc cranial stereotactic radiosurgery: implications of multileaf collimator margin on dose-volume metrics.

Tanyi JA, Doss EJ, Kato CM, Monaco DL, ZMeng L, Chen Y, Kubicky CD, Marquez CM, Fuss M.

Br J Radiol. 2012 Nov;85(1019):e1058-66. doi: 10.1259/bjr/79414773.

50.

Genomic DNA copy-number alterations of the let-7 family in human cancers.

Wang Y, Hu X, Greshock J, Shen L, Yang X, Shao Z, Liang S, Tanyi JL, Sood AK, Zhang L.

PLoS One. 2012;7(9):e44399. doi: 10.1371/journal.pone.0044399. Epub 2012 Sep 6.

Supplemental Content

Support Center